OncoTherics is a new pharmaceutical company, focusing on the development of novel hypoxia-activated pro-drugs for the treatment of a wide range of cancers... The company was formed as a spin-out from BioStatus, to progress a novel small molecule, code-named OCT1002. The company is at an early stage but the patented technology has a unique history allowing a more rapid than usual progression through the clinical trial process. For further information, please contact us using the contact form provided on this site ...
| Website | http://www.oncotherics.com |
| Revenue | $4 million |
| Employees | 6 (2 on RocketReach) |
| Founded | 2009 |
| Phone | +44 1509 558163 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+10 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Business Services General, Hypoxia activated prodrugs for the treatment of cancer, Business Services |
| Keywords | Cancer Treatment, Pharmaceutical Research, Oncology Therapeutics, Novel Drug Development, Small Molecule Drugs, Cancer Drug Discovery, Drug Development, Biopharmaceutical, Clinical Trials, Cancer Research, Pharmaceutical, Therapeutics, New Drugs, Cancer Therapies, Oncology, Drug Discovery |
| Competitors | Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Lilly India +51 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541714 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies |
Looking for a particular OncoTherics employee's phone or email?
The OncoTherics annual revenue was $4 million in 2026.
Thomas Morris is the Chief Medical Officer of OncoTherics.
2 people are employed at OncoTherics.
The NAICS codes for OncoTherics are [541714, 54171, 54, 5417, 541].
The SIC codes for OncoTherics are [873, 87].